Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer

Journal of Urology

Volumn 155, Issue 3, 1996, Pages 888-894

  Mizutani, Youichi ^a   Okada, Yusaku ^a   Terachi, Toshiro ^a   Yoshida, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

bladder neoplasms; cytotoxicity, immunologic; lymphocytes

Indexed keywords

ARTICLE; BLADDER CARCINOMA; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CELLULAR IMMUNITY; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

EID: 0030053472     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66335-3     Document Type: Article

References (28)

1. Mizutani, Y., Nio, Y., Fukumoto, M. and Yoshida, O.: Effects of bacillus Calmette-Guérin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer, 69:537, 1992.
2. Shapiro, A., Ratliff, T. L., Oakley, D. M. and Catalona, W. J.: Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guérin and its correlation with bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res., 43: 1611, 1983.
3. Takasugi, M., Mickey, M. R. and Terasaki, P. I.: Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res., 33: 2898, 1973.
4. Peter, H. H., Pavie-Fischer, J., Fridman, W. H., Aubert, C., Cesarini, J. P., Roubin, R. and Kourilsky, F.: Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J. Immunol., 115: 539, 1975.
5. Herberman, R. B. and Ortaldo, J. R.: Natural killer cells: their roles in defenses against disease. Science, 214: 24, 1981.
6. Haller, O., Hansson, M., Kiessling, R. and Wigzeli, H.: Role of non-conventional natural killer cells in resistance against syngeneic tumor cells in vivo. Nature, 270: 609, 1977.
7. Baldwin, R. W.: Immune surveillance revisited. Nature, 270: 557, 1977.
8. Ritz, J.: The role of natural killer cells in immune surveillance. New Engl. J. Med., 320: 1748, 1989.
9. Becker, S., Kiessling, R., Lee, N. and Klein, G.: Modulation of sensitivity to natural killer cell lysis after in vitro explantation of a mouse lymphoma. J. Natl. Cancer Inst., 61: 1495, 1978.
10. Uchida, A. and Mizutani, Y.: Autologous tumor killing activity in human. Mechanisms and biological significance. In: New Horizons in Tumor Immunotherapy. Edited by Y. Torisu and T. Yoshida. Amsterdam: Elsevier Science Publishers, p. 201, 1989.
11. Akiyoshi, T., Koba, F., Arinaga, S. and Ueo, H.: Preoperative cell-mediated immune function and the prognosis of patients with gastric carcinoma. J. Surg. Oncol., 45: 137, 1990.
12. Hersey, P., Edwards, A., Milton, G. W. and McCarthy, W. H.: No evidence for an association between natural killer cell activity and prognosis in melanoma patients. Natural Immunity Cell Growth Regulation, 3: 87, 1983.
13. Vánky, F., Willems, J., Kreicbergs, A., Aparisi, T., Andréen, M., Broström, L. A., Nilsonne, U., Klein, E. and Klein, G.: Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course. I. Evaluation of 46 patients with sarcoma. Cancer Immunol. Immunother., 16: 11, 1983.
14. Vánky, F., Péterffy, A., Böök, K., Willems, J., Klein, E. and Klein, G.: Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course. II. Evaluation of 69 patients with lung carcinoma. Cancer Immunol. Immunother., 16: 17, 1983.
15. Mizutani, Y., Bonavida, B., Nio, Y. and Yoshida, O.: Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer, 71: 1313, 1993.
16. Mizutani, Y., Nio, Y. and Yoshida, O.: The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to the autologous peripheral blood lymphocytes. Cancer, 69: 2999, 1992.
17. Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y. and Yoshida, O.: Sensitization of human renal cell carcinoma cells to cis-diamminedichroloplatinum (II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res., 55: 590, 1995.
18. Mizutani, Y., Fukumoto, M., Bonavida, B. and Yoshida, O.: Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer, 74: 2546, 1994.
19. Mizutani, Y., Nio, Y. and Yoshida, O.: Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to blood and lymphokine activated killer cells. J. Urol., 147: 505, 1992.
20. Mizutani, Y., Nio, Y. and Yoshida, O.: Effect of PSK and its subfractions on peripheral blood lymphocytes mediated cytotoxicity against urinary bladder tumor cells. J. Urol., 148: 1571, 1992.
21. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Cater, C., Bock, S., Schwartzentruber, D., Wei, J. P. and White, D. E.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl. J. Med., 319: 1676, 1988.
22. Rosenberg, S. A., Spiess, P. and Lafreniere, R.: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 223: 1318, 1986.
23. Mizutani, Y. and Yoshida, O.: Activation by the protein-bound polysaccharide PSK (Krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer. J. Urol., 145: 1082, 1991.
24. Mizutani, Y., Bonavida, B., Fukumoto, M. and Yoshida, O.: Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes. J. Immunother., 17: 78, 1995.
25. Lamm, D. L., Thor, D. E., Winters, W. D., Stogdill, V. D. and Radwin, H. M.: BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses. Cancer, 48: 82, 1981.
26. Herr, H. W., Laudone, V. P. and Whitmore, W. F., Jr.: An overview of intravesical therapy for superficial bladder tumors. J. Urol., 138: 1363, 1987.
27. Kelley, D. R., Haaff, E. O., Becich, M., Lage, J., Bauer, W. C., Dresner, S. M., Catalona, W. J. and Ratliff, T. L.: Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J. Urol., 135: 268, 1986.
28. Fleischmann, J. D., Toossi, Z., Ellner, J., Wentworth, D. B., Ratliff, T. L. and Imbembo, A. L.: Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer, 64: 1447, 1989.